

## Dornier collaborates with NUH to initiate new clinical study

21 November 2018 | News

**Dornier ARIES offers non-invasive Li-SWT, which has been validated as a treatment for many urology and orthopedic associated conditions with high levels of efficacy and safety.**



**Singapore** – Dornier MedTech, a global leader in urology, announced the initiation of a new clinical study to determine the safety and efficacy of low-intensity shockwave therapy (Li-SWT) to alleviate symptoms of Myofascial Trigger Point (MTrP)-associated Chronic Pelvic Pain Syndrome (CPPS). The study will be performed in collaboration with the National University Hospital (NUH) Urology Centre. NUH is the first public hospital in Singapore to use Li-SWT to treat Erectile Dysfunction, and the technique is now being applied to CPPS.

CPPS is characterized by episodes of pain and discomfort in the perineum and private parts, demarcated by an area below the navel and between the hips. Affecting both men and women, the pain varies in severity and duration, and can be triggered while performing activities as simple as sitting for a long time, urinating or having a bowel movement. CPPS can detrimentally affect a patient's quality of life if left untreated. It is estimated that CPPS affects up to 14% of the global male population and about 9% of men in Asia Pacific.

One underlying cause of CPPS is the development of active MTrPs, which are painful nodules or contractions in the pelvic floor muscles and in surrounding connective tissue known as the fascia. MTrPs are an often-overlooked cause of pelvic pain. Current therapies for MTrPs include muscle relaxants, needling, and manual trigger point release therapy. These therapies may be associated with undesirable side effects, relapse, or pain during treatment.

Dornier ARIES offers non-invasive Li-SWT, which has been validated as a treatment for many urology and orthopedic associated conditions with high levels of efficacy and safety. Li-SWT could potentially be a fast and relatively pain-free treatment modality with a lasting outcome for MTrP-associated CPPS.

The single-arm study will be conducted by Dr Joe Lee (Consultant, Department of Urology and Director of Andrology & Male Reproductive Medicine, NUH). The study will enroll up to 20 male patients between the ages of 21 and 85 suffering from chronic pelvic pain for more than 3 months and who have failed at least one course of systemic treatment. Patients will be

assessed for erectile function, pain and quality of life before and after treatment.

Wong Yau Chung, Head, Dornier ARIES Group, said: "Chronic Pelvic Pain Syndrome is a globally prevalent syndrome, notorious for the pain and disability it causes to patients' most basic daily activities. The initiation of this clinical study demonstrates our commitment to improving patients' quality of life using innovative products that are supported by robust clinical evidence. As a leading medical technology company, we look forward to providing scientifically proven solutions for physicians in the treatment of chronic pelvic pain."